The latest announcement is out from Jiangsu Recbio Technology Co., Ltd. Class H ( ($HK:2179) ). Jiangsu Recbio Technology Co., Ltd. has received ...
Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollm ...
Cyprus Mail on MSN
Cypriot innovation heads to Slush 2025
The Research and Innovation Foundation (RIF) is leading a national delegation of 13 startups to Slush 2025 in Helsinki, one ...
At the 17th PEGS Europe Protein & Antibody Engineering Summit, Creative Biolabs didn't just bring a "booth"—it brought a ...
Zacks Small Cap Research on MSN
DYAI: Purchase Orders Rolling In
DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced third quarter 2025 results on November 12th, 2025, and held a conference call to discuss them after ...
Whether infection of cells by individual virions occurs randomly or if there is some form (s) of competition or cooperativity between individual virions remains largely unknown for most virus-cell ...
The fibroblast growth factor market presents opportunities in regenerative medicine, oncology, and metabolic disorders due to advances in molecular biology and delivery technologies. Key opportunities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback